Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions

Cardiovasc Res. 2021 Dec 17;117(14):2699-2701. doi: 10.1093/cvr/cvab129.

Authors

Coert J Zuurbier¹, Antonius Baartscheer², Cees A Schumacher², Jan W T Fiolet², Ruben Coronel²

Affiliations

¹ Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Intensive Care and Anesthesiology, Department of Anesthesiology, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
² Amsterdam UMC, University of Amsterdam, Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.

No abstract available

Publication types

Letter

MeSH terms

Action Potentials / drug effects*
Animals
Benzhydryl Compounds / pharmacology*
Buffers
Glucosides / pharmacology*
Hydrogen-Ion Concentration
Male
Myocytes, Cardiac / drug effects*
Myocytes, Cardiac / metabolism
Rabbits
Sodium-Glucose Transporter 2 Inhibitors / pharmacology*
Sodium-Hydrogen Exchanger 1 / antagonists & inhibitors*
Sodium-Hydrogen Exchanger 1 / metabolism

Substances

Benzhydryl Compounds
Buffers
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Hydrogen Exchanger 1
empagliflozin